Lin Bioscience (6696.TWO) Aktie Kurs

Lin Bioscience Kurs

LUKKET
162,50
​
Markedet lukket

Lin Bioscience aktiekurs

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Lin Bioscience aktie og aktieanalyse

Lin BioScience, Inc. engages in the development of drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-10-08. The firm is in the research and development and clinical trials stage. The company has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.

Hyppigt stillede spørgsmål om Lin Bioscience-aktien

Omregnet til den aktuelle valutakurs handles Lin Bioscience-aktien til 4,45 EUR (162,50 TWD).

Omsætningen kan for øjeblikket ikke beregnes for Lin Bioscience.

Overskuddet kan for øjeblikket ikke beregnes for Lin Bioscience.

P/E-forholdet kan ikke beregnes for Lin Bioscience i øjeblikket.

P/S-forholdet kan ikke beregnes for Lin Bioscience i øjeblikket.

AlleAktien-kvalitetsscore for Lin Bioscience er 2/10.

ISIN for Lin Bioscience er TW0006696008. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

Tickeren for Lin Bioscience er 6696.TWO. Tickersymbolet bruges til at handle Lin Bioscience-aktier på børsen.

Fair værdiTerminal
134,88 TWD
Over-/underværdieringTerminal
Fair værdieret
Sektor
Industri
Bioteknologi
Antal aktier
Medarbeidere
Omsætningsvækst Ø5 år
EBIT-vækst Ø5 år
Resultatvækst Ø5 år
Land
Taiwan
Valuta
TWD
Børsintroduktion
8. okt. 2018
ISIN
TW0006696008
CUSIP
Y528A2107
Markedsværdi
52-ugers interval
AAQS
2 / 10
PEG-forhold
—
P/E-forhold
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
K/B-forhold
1,25
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-12,70 %
Sidst opdateret 23. okt. 2026, 18.18

Lin Bioscience Peer Group

Lin Bioscience FIGI

6696:TT (Taipei Stock Exchange) · BBG00M3JS3K7